Cookies

We use cookies to customise content for your subscription and for analytics.
If you continue to browse the International Law Office website, we will assume you are happy to receive all of our cookies. For further information please read our Cookie Policy.

Your Subscription

We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.





Login
Twitter LinkedIn




Login
  • Home
  • About
  • Updates
  • Awards
  • Contact
  • Directory
  • OnDemand
  • Partners
  • Testimonials
Forward Share Print
Smart & Biggar

New oncology initiative and Health Canada study on biosimilar drugs

Newsletters

05 June 2019

Healthcare & Life Sciences Canada


The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a pan-Canadian Oncology Biosimilars Initiative, which aims to ensure appropriate implementation and cost-effective use of therapeutic oncology biosimilars across Canada. In November 2018 the initiative held a pan-Canadian Oncology Biosimilars Summit. The initiative has released a summit proceedings report and an initiative action plan.

Separately, Health Canada announced that it is collaborating with the Drug Safety and Effectiveness Network on a project to study patients with inflammatory rheumatic diseases and inflammatory bowel disease who are taking biologic drugs.(1) The study aims to compare the safety and effectiveness of biosimilar drugs to the reference biologic drug.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (uawojtyra@smart-biggar.ca). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.

Endnotes

(1) The protocol for the study is available here.

The materials contained on this website are for general information purposes only and are subject to the disclaimer.

ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.

Forward Share Print

Author

Urszula Wojtyra

Urszula Wojtyra

Register now for your free newsletter

View recent newsletter

More from this firm

  • Federal Court issues two interlocutory decisions in Section 8 pregabalin case
  • Update on biosimilars
  • Amgen not precluded from litigating same patent under amended PMNOC regulations
  • PMPRB news
  • Competition Bureau concludes investigation into alleged restrictions of off-label use of vaccines

More articles

  • Home
  • About
  • Updates
  • Awards
  • Contact
  • My account
  • Directory
  • OnDemand
  • Partners
  • Testimonials
  • Follow on Twitter
  • Follow on LinkedIn
  • Disclaimer
  • Privacy policy
  • GDPR Compliance
  • Terms
  • Cookie policy
Online Media Partners
Inter-Pacific Bar Association (IPBA) International Bar Association (IBA) European Company Lawyers Association (ECLA) Association of Corporate Counsel (ACC) American Bar Association Section of International Law (ABA)

© 1997-2019 Law Business Research

You need to be logged in to make a comment. Log in here.
Many thanks. Your comment has been sent.

Your details



Your comment or question *